Thymosin Beta-4

Thymosin beta-4 is one of the most abundant intracellular peptides in mammalian cells and the principal G-actin buffer. Beyond actin, it upregulates laminin-5 and integrin-linked kinase, suppresses NF-kB-driven inflammatory signalling, and promotes progenitor cell recruitment into injured tissue - the combination is why it accelerates epithelial closure in cornea and skin. It has been formulated as ophthalmic drops (RGN-259) for dry eye and neurotrophic keratopathy, as a topical gel (RGN-137) for wounds, and as an intravenous agent (RGN-352) for cardiac and neurological injury. The ophthalmic programme is the one that reached late-stage randomised trials, with mixed but partly positive results on ocular discomfort and corneal staining.

Targets: G-actin, Integrin-linked kinase, Laminin-5, NF-kB inflammatory signalling

• · There is no validated human dose for systemic musculoskeletal use; this is simply the TB-500 convention applied to the full peptide.
• · RGN-259 trials used a 0.1 percent preservative-free ophthalmic solution over 28 days. This is a compounded formulation, not something to improvise from an injection vial.

Work out your exact syringe units →

• commonInjection-site reaction
• commonTransient fatigue— Same pattern as TB-500 loading.
• commonTransient ocular stinging with drops— The most frequent adverse event in the dry eye trials, and generally brief.

• Active malignancy - elevated thymosin beta-4 expression correlates with invasiveness and metastasis in several cancers, which makes systemic dosing a poor idea around known tumour tissue.

• redundanttb-500 — Same active biology; running both is duplication.
• synergybpc-157 — The standard complementary pairing for soft-tissue repair.

• · No established bloodwork for systemic use.
• · For ocular use, changes should be tracked by an ophthalmologist with corneal staining rather than by symptoms alone.

Not an approved drug in the US or EU; the ophthalmic form remains investigational. Sold as a research chemical for injectable use. WADA-prohibited.

• ARISE dry eye disease trial programme of RGN-259 (thymosin beta-4 ophthalmic solution) (trial)
• Goldstein & Kleinman, thymosin beta-4 in wound healing and tissue regeneration (review) (review)
• Bock-Marquette et al. 2004, Nature, thymosin beta-4 and cardiac repair (preclinical)

Thymosin beta-4 is one of the most abundant intracellular peptides in mammalian cells, and its housekeeping job is to hold the unpolymerised G-actin pool so a cell can rebuild its cytoskeleton fast. That is the textbook function, and it is intracellular - which means it does not, on its own, explain what happens when you drip the peptide onto a cornea or infuse it into a vein. The therapeutic mechanism is better understood as a set of extracellular signalling effects. It activates integrin-linked kinase and Akt, promoting cell survival and migration. It upregulates laminin-5, which is the anchoring filament protein epithelial cells need in order to adhere to and crawl across a basement membrane - and that is the specific reason it works in corneal epithelial defects, where the failure mode is exactly an epithelium that will not adhere and migrate. It suppresses NF-kB-driven inflammatory transcription, which is why the ocular trials showed reductions in discomfort as well as staining. And it recruits progenitor cells into injured tissue. The clinical picture that produces is faster re-epithelialisation with less inflammation and less scar - not more tissue, better organised tissue arriving sooner. That is why the strongest human results are in cornea, where the endpoint is epithelial closure over days, and why the systemic musculoskeletal use has never produced a comparably clean result. The antifibrotic arm is partly a metabolite story. Ac-SDKP, cleaved from the N-terminus, inhibits fibroblast proliferation and collagen deposition and is degraded by ACE. That connects thymosin beta-4 biology to the renin-angiotensin system in a way that is rarely mentioned and is worth knowing if you are also running an ACE inhibitor. The malignancy caveat is the same as for TB-500 and applies with equal force to the full-length peptide: elevated thymosin beta-4 expression correlates with invasiveness and metastatic potential in several cancers.

The dominant failure is category confusion. Thymosin beta-4 has genuine randomised human data - in eyes. People read 'randomised placebo-controlled trial' and apply the credibility to a subcutaneous shot for a hamstring, which has never been tested in a human. The evidence does not transfer across route and indication. The second is the improvised eye drop. It is the obvious move once you have a vial, and it is the wrong one. Sterility, tonicity, pH and preservative all matter on a cornea, and the compounded 0.1 percent preservative-free solution used in trials is not something to reproduce at a kitchen table. The third is dosing systemically by TB-500 convention. The 2-2.5 mg twice weekly loading schedule was never derived for the full-length peptide, which is roughly three and a half times the molecular weight of the heptapeptide. Whether you should dose by mass or by moles has never been addressed by anyone, and the honest answer is that no validated human systemic dose exists. The fourth is the malignancy question, which is identical to TB-500's and just as unresolved.

• G-actin (monomeric actin) — Low micromolar dissociation constant for the intact peptide

  Sequesters actin monomers to buffer the polymerisable pool. The canonical intracellular function.

• Integrin-linked kinase (ILK) / Akt — Not a direct binding interaction with a published constant

  Cell survival and migration signalling; identified in the cardiac repair work as the key downstream pathway.

• Laminin-5 — Transcriptional upregulation rather than binding

  Provides the anchoring substrate epithelial cells need to adhere and migrate. The specific reason corneal epithelial defects close faster.

• NF-kB inflammatory transcription — Not characterised

  Suppression of pro-inflammatory cytokine output, contributing to the symptom relief seen in the dry eye trials independent of the healing effect.

• Ac-SDKP / ACE axis (via metabolite) — Ac-SDKP is a well-characterised ACE substrate

  Antifibrotic signalling through inhibition of fibroblast proliferation and collagen deposition. Levels rise when ACE is inhibited.

• RGN-259 (thymosin beta-4 0.1 percent ophthalmic solution) phase 2 randomised trial in severe dry eye Phase 2 · n=9 · 8 weeks · 2015

  28 days of treatment plus 28 days of follow-up. At day 56 the treated group showed a 35.1 percent reduction in ocular discomfort and a 59.1 percent reduction in total corneal fluorescein staining versus vehicle, with improved tear break-up time and tear production. Very small - nine patients, twelve treated eyes against six control eyes - so treat it as a positive signal rather than a settled result.

• ARISE dry eye disease trial programme (RGN-259) Phase 3

  A series of larger randomised placebo-controlled trials in dry eye disease with mixed results across sign and symptom endpoints. Widely referenced but the individual ARISE trial reports could not be resolved to indexed publications in the preparation of this entry, so participant numbers and outcomes are not stated here.

Ophthalmic: measurable change in corneal staining within days, with the trial endpoint at 28 days. Symptom improvement tends to lag the sign improvement. Dermal wounds: epithelial effects over days to two weeks, consistent with epithelial turnover. Systemic soft tissue: no trial data. If you are extrapolating from TB-500 practice, the answer is two to four weeks before anything is judgeable and six weeks before a decision, but understand that this is a convention borrowed from a different molecule. Intravenous: plasma levels are gone in one to two hours; any effect you observe after that is downstream biology, not circulating drug.

With BPC-157 this is the standard complementary pairing for soft tissue, on the same logic as the TB-500 stack: perfusion plus migration. With TB-500 it is redundant. Same biology, frequently the same molecule. With GHK-Cu for dermal wounds and post-surgical scar the combination targets both closure speed and matrix quality, which is the most coherent version of a 'wound healing stack'. The interaction nobody mentions: ACE inhibitors. Ac-SDKP, the antifibrotic metabolite of thymosin beta-4, is degraded by ACE, so ACE inhibition raises and prolongs it. That is a plausible potentiation of the antifibrotic arm and it has never been studied in combination. Not a reason to avoid either, but worth knowing. And the hard rule for the ocular route: do not improvise eye drops from an injection vial reconstituted in bacteriostatic water. Benzyl alcohol on a cornea is a genuinely bad idea, and the trials used a preservative-free ophthalmic formulation for exactly that reason.

Against TB-500: the same biology, but you are buying the molecule that has actually been through randomised human trials rather than a fragment defined by vendor convention. If the price difference is small, this is the more defensible purchase. Against BPC-157 for a specific tendon: BPC-157 is cheaper, dosed locally and daily, and has a larger rodent literature for tendon specifically. Thymosin beta-4's strength is epithelial and vascular tissue, not tendon. Against approved treatments for dry eye - cyclosporine, lifitegrast, autologous serum drops: those are prescribable now and have far larger trial bases. RGN-259 is not available as an approved product anywhere, so this comparison is theoretical unless you are in a trial. Against GHK-Cu for skin: GHK-Cu has better topical human evidence and is available as a finished cosmetic product. Thymosin beta-4 for skin is an injectable extrapolation.

$60–$200/month. Order-of-magnitude estimate for research-chemical injectable vials at TB-500-style dosing. The ophthalmic formulation is investigational and not commercially priced. Not price-checked in the preparation of this entry.

• ?No published human pharmacokinetics beyond an approximate one-to-two-hour plasma half-life after intravenous dosing. No tmax, volume of distribution, clearance or protein binding figure.
• ?The individual ARISE phase 3 trial reports could not be resolved to indexed publications in this session, so the programme is described but its numbers are not stated.
• ?There is no validated human dose for systemic musculoskeletal use, and no guidance on whether to dose equimolar or equimass relative to TB-500.
• ?How much of the antifibrotic effect is thymosin beta-4 itself versus the Ac-SDKP metabolite is unresolved.
• ?The theoretical malignancy concern rests on tumour expression-correlation data, not on any study of exogenous administration.
• ?Cost figures are estimates and were not price-verified in this session.

• Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial Sosne G, Ousler GW, Cornea, 2015 · PMID 25826322

  The clearest published randomised human result for thymosin beta-4 in any indication. Small, but a real trial with objective endpoints.

• Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D, Nature, 2004 · PMID 15565145

  The mechanistic foundation - ILK and Akt activation as the route by which an extracellular peptide produces migration and survival effects.